澳大利亚科学家进行血液测试,以监测脑肿瘤治疗情况,提供更快、较少侵入性的替代方法,取代计量吸入器。 Australian scientists create blood test to monitor brain tumor treatment, offering faster, less invasive alternative to MRIs.

澳大利亚科学家开发了一项新的血液测试,检测血液中的微小生物微粒,以监测脑肿瘤对治疗的反应,为频繁的计量吸入器提供了更快、较少侵入性的替代方法。 A new blood test developed by Australian scientists detects tiny biological particles in the bloodstream to monitor brain tumor response to treatment, offering a faster, less invasive alternative to frequent MRIs. 该测试使用一种苯型分析器芯片来识别肿瘤细胞释放的细胞外卵囊,使医生能够实时评估治疗效果,只使用少量血液样本。 The test, which uses a phenotype analyzer chip to identify extracellular vesicles released by tumor cells, allows doctors to assess treatment effectiveness in real time with just a small blood sample. 这样做可以更快地调整治疗,减轻病人负担,改善脑癌病人,特别是地区脑癌病人的治疗结果。 This could enable quicker adjustments to therapy, reduce patient burden, and improve outcomes for brain cancer patients, particularly those in regional areas. 该技术由Mark Hughes基金会资助,准备在《科学进步》中发表,是个人化脑癌护理的重要一步。 The technology, funded by the Mark Hughes Foundation and set for publication in Science Advances, represents a significant step toward personalized brain cancer care.